Search results for " Parkinson’s disease"

showing 10 items of 22 documents

The predictive power of transcranial sonography in movement disorders: a longitudinal cohort study.

2018

Transcranial sonography (TCS) is a noninvasive, easily performed, and commonly available neuroimaging technique useful for the study of brain parenchyma in movement disorders. This tool has been increasingly used in the diagnosis of Parkinson’s disease and atypical parkinsonism. The aim of the study was to evaluate the applicability of this technique as supportive tool in the early diagnosis of movement disorders. We performed TCS on 315 individuals which were diagnosed as healthy controls or affected by idiopathic Parkinson’s disease, monogenetic subtypes of Parkinson’s disease, atypical parkinsonism, and Dementia with Lewy bodies. Five TCS diagnostic patterns were defined on the basis of …

0301 basic medicineMalemedicine.medical_specialtyMovement disordersNeurologyUltrasonography Doppler TranscranialConcordanceDementia with Lewy bodiesDermatologyDiseaseCohort Studies03 medical and health sciences0302 clinical medicineNeuroimagingPredictive Value of TestsInternal medicineSubstantia nigramedicineLenticular nucleiHumansNeuroradiologyAgedMovement DisordersDementia with Lewy bodiesbusiness.industryfungiGeneral MedicineMiddle Agedmedicine.diseasePsychiatry and Mental health030104 developmental biologyAtypical parkinsonismIdiopathic Parkinson’s diseaseTranscranial sonographySettore MED/26 - NeurologiaFemaleNeurology (clinical)Neurosurgerymedicine.symptombusiness030217 neurology & neurosurgeryNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
researchProduct

Vascular risk factors, white matter lesions and cognitive impairment in Parkinson’s disease: the PACOS longitudinal study

2020

Abstract Background Vascular risk factors (VRFs) may be associated with cognitive decline in early Parkinson’s disease (PD) but results are inconclusive. The identification of modifiable risk factors is relevant for prevention and treatment. Methods Parkinson’s disease (PD) patients of the PACOS cohort who underwent a baseline and follow-up neuropsychological evaluation were enrolled in the study. PD with Mild Cognitive Impairment (MCI) and dementia (PDD) were diagnosed according to the MDS criteria. A Baseline 1.5 T brain MRI was used to calculate the white matter lesions (WMLs) burden using the Wahlund visual scale. Laboratory data, presence of hypertension, diabetes and use of anti-hyper…

0301 basic medicinemedicine.medical_specialtyEpidemiologyNeuropsychological Testsbehavioral disciplines and activitiesWhite matter lesions03 medical and health sciences0302 clinical medicineInternal medicinemental disordersEpidemiologyHumansMedicineDementiaCognitive DysfunctionLongitudinal StudiesRisk factorCognitive declineOriginal CommunicationFramingham Risk Scorebusiness.industryMild cognitive impairmentParkinson DiseaseEpidemiology Hypertension Mild cognitive impairment Parkinson’s disease Risk factors White matter lesions Humans Longitudinal Studies Neuropsychological Tests Risk Factors Cognitive Dysfunction Parkinson Disease White Mattermedicine.diseaseWhite MatterHyperintensitynervous system diseases030104 developmental biologyBlood pressureRisk factorsNeurologyHypertensionCohortParkinson’s diseaseNeurology (clinical)business030217 neurology & neurosurgeryJournal of Neurology
researchProduct

Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease.

2018

The diagnosis of Parkinson’s disease (PD) is based on clinical features and differently to the common opinion that detecting this condition is easy, seminal clinico-pathological studies have shown that up one-fourth of patients diagnosed as PD during life has an alternative diagnosis at post-mortem. The misdiagnosis is even higher when only the initial diagnosis is considered, since the diagnostic accuracy improves by time, during follow-up visits. Given that the confirmation of the diagnosis of PD can be only obtained through neuropathology, to improve and facilitate the diagnostic-therapeutic workup in PD, a number of criteria and guidelines have been introduced in the last three decades.…

0301 basic medicinemedicine.medical_specialtyParkinson's disease diagnostic criteriapreclinical Parkinson’s diseaseParkinson's diseaseParkinson’s disease guidelinesNeuropathologyDiseaseReviewlcsh:RC346-429prodromal Parkinson’s disease03 medical and health sciences0302 clinical medicinePreclinical Parkinson's diseasemedicineProdromal Parkinson's diseaseIntensive care medicinelcsh:Neurology. Diseases of the nervous systemJames Parkinsonbusiness.industryTask forceNoveltymedicine.diseaseClinical trial030104 developmental biologyNeurologyClinical diagnosisParkinson's disease guidelineParkinson’s disease diagnostic criteriaNeurology (clinical)Early phasebusiness030217 neurology & neurosurgeryNeuroscienceFrontiers in neurology
researchProduct

Transcranial random noise stimulation over the primary motor cortex in PD-MCI patients: a crossover, randomized, sham-controlled study

2020

AbstractMild cognitive impairment (MCI) is a very common non-motor feature of Parkinson’s disease (PD) and the non-amnestic single-domain is the most frequent subtype. Transcranial random noise stimulation (tRNS) is a non-invasive technique, which is capable of enhancing cortical excitability. As the main contributor to voluntary movement control, the primary motor cortex (M1) has been recently reported to be involved in higher cognitive functioning. The aim of this study is to evaluate the effects of tRNS applied over M1 in PD-MCI patients in cognitive and motor tasks. Ten PD-MCI patients, diagnosed according to the Movement Disorder Society, Level II criteria for MCI, underwent active (re…

0301 basic medicinemedicine.medical_specialtyParkinson's diseaseNeurologyPrefrontal CortexNeurology and Preclinical Neurological Studies - Original ArticleTranscranial Direct Current Stimulation03 medical and health sciencesCognition0302 clinical medicinePhysical medicine and rehabilitationSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.medicineMemory spanHumansCognitive DysfunctionBiological Psychiatrybusiness.industryMotor CortexParkinson DiseaseCognitionmedicine.diseaseCognitive impairment Motor cortex Parkinson’s disease Transcranial random noise stimulationTranscranial random noise stimulationDorsolateral prefrontal cortexPsychiatry and Mental healthCognitive impairment030104 developmental biologymedicine.anatomical_structureNeurologyParkinson’s diseaseSettore MED/26 - NeurologiaNeurology (clinical)Primary motor cortexbusiness030217 neurology & neurosurgeryStroop effectMotor cortexJournal of Neural Transmission
researchProduct

Urological dysfunctions in patients with Parkinson’s disease: clues from clinical and non-invasive urological assessment

2018

Abstract Background Autonomic nervous system dysfunction, common in patients with Parkinson’s disease (PD), causes significant morbidity and it is correlated with poor quality of life. To assess frequency of urinary symptoms in patients with PD, without conditions known to interfere with urinary function. Methods Non-demented PD patients were consecutively enrolled from the outpatients clinic of our department. Scales investigating motor and non-motor symptoms were carried out. Evaluation of urinary dysfunctions was carried out using the AUTonomic Scale for Outcomes in Parkinson’s disease (SCOPA-AUT) questionnaire. Patients underwent noninvasive urological studies (nUS), including uroflowme…

AdultMaleUrologic Diseasesmedicine.medical_specialtyNeurologyParkinson's diseaseUrinary systemAutonomic dysfunction030232 urology & nephrologyNon-motor symptomsUrinary symptomsDiseaseNon-motor symptomlcsh:RC346-429SCOPA-AUT03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesInternal medicinemedicineHumansNeurochemistryStage (cooking)lcsh:Neurology. Diseases of the nervous systemAgedbusiness.industryAUTonomic SCale for outcomes in Parkinson’s diseaseParkinson DiseaseGeneral MedicineMiddle AgedUrinary functionmedicine.diseaseAutonomic Nervous System DiseasesQuality of LifeParkinson’s diseaseFemaleSettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusiness030217 neurology & neurosurgeryBMC Neurology
researchProduct

A Diet for Dopaminergic Neurons?

2009

Parkinson's disease (PD) is the second most common neurodegenerative disease, which unfortunately is still fatal. Since the discovery of dopamine (DA) neuronal cell loss within the substantia nigra in PD, the past decades have seen the understanding of the pathophysiological mechanisms underlying the degenerative process advance at a very impressive rate. Nevertheless, there is at present no cure for PD. Although there are no proven therapies for prevention, a large body of evidence from animal studies has highlighted the paramount role of dietary factors in counteracting DA degeneration. Consistently, associations between the risk of developing PD and the intake of nutrients, individual fo…

Dietary recommendations Dopaminergic neurons Neurodegeneration Neuroprotection Parkinson’s disease PreventionSettore BIO/09 - Fisiologia
researchProduct

Fibroblast growth factor-21 enhances mitochondrial functions and increases the activity of PGC-1α in human dopaminergic neurons via Sirtuin-1

2014

Abstract Mitochondrial dysfunctions accompany several neurodegenerative disorders and contribute to disease pathogenesis among others in Parkinson’s disease (PD). Peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) is a major regulator of mitochondrial functions and biogenesis, and was suggested as a therapeutic target in PD. PGC-1α is regulated by both transcriptional and posttranslational events involving also the action of growth factors. Fibroblast growth factor-21 (FGF21) is a regulator of glucose and fatty acid metabolism in the body but little is known about its action in the brain. We show here that FGF21 increased the levels and activity of PGC-1α and elevated mito…

FGF21educationRegulatorNicotinamide phosphoribosyltransferasePGC-1αFGF21; PGC-1α; SIRT1; Dopaminergic neurons; Mitochondria; Parkinson’s diseaseMitochondrionBioinformaticsDopaminergic neuronsSettore BIO/09 - Fisiologia03 medical and health scienceschemistry.chemical_compoundFGF21SIRT10302 clinical medicineDopaminergic Cell030304 developmental biologyDopaminergic neuron0303 health sciencesMultidisciplinarybiologySirtuin 1ResearchDopaminergicMitochondriaCell biologychemistryParkinson’s diseasebiology.protein3111 BiomedicineNAD+ kinase030217 neurology & neurosurgerySpringerPlus
researchProduct

THE ENTERIC NERVOUS SYSTEM: NEW DEVELOPMENTS AND EMERGING CONCEPTS

2011

The enteric nervous system (ENS) is an integrative neuronal network, organized in two ganglionated plexuses, myenteric and submucosal, composed of neurons and enteric glial cells, controlling the activity of the smooth muscle of the gut, mucosal secretion and blood flow. The ENS contains as many neurons as the spinal cord, and the functional and chemical diversity of enteric neurons closely resembles that of the central nervous system. This highly integrated neural system is also referred to as the ‘brain-in-the-gut’, because of its capability to function in the absence of nerve inputs from the central nervous system.

Gastrointestinal system -- Innervation -- Physiologynervous systemGastrointestinal system -- InnervationParkinson’s diseaseParkinson's disease -- TreatmentneurotransmissionEnteric nervous systemEnteric nervous system; neurotransmission; Parkinson’s disease
researchProduct

Effects of a Resistance Training Protocol on Physical Performance, Body Composition, Bone Metabolism, and Systemic Homeostasis in Patients Diagnosed …

2022

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by motor impairments and it is correlated with loss of bone mineral density. This study aimed to analyze the effects of resistance training on bone metabolism, systemic homeostasis, body composition, and physical performance in people with PD. Thirteen subjects (age 64.83 ± 5.70) with PD diagnosis were recruited. Participants performed neuromuscular tests, body composition assessment, and blood sample analysis at baseline, and after an 11 weeks-training period. Each training session lasted 90 min, three times a week. The participants had significant improvements in the timed up and go (p < 0.01), sit to stand (p < …

Health Toxicology and MutagenesisOsteocalcinPublic Health Environmental and Occupational Healthphysical activityResistance TrainingParkinson DiseasePilot ProjectsMiddle AgedPhysical Functional Performanceosteogenesiphysical activity; neurodegenerative disease; resistance training; bone resorption; osteogenesis; osteoporosis; Parkinson’s diseaseneurodegenerative diseaseParkinson’s diseaseBody CompositionHumansHomeostasisosteoporosiCalciumVitamin Dbone resorptionAgedInternational Journal of Environmental Research and Public Health; Volume 19; Issue 20; Pages: 13022
researchProduct

Analysis of the LRP10 gene in patients with Parkinson's disease and dementia with Lewy bodies from Southern Italy

2020

Recently, the LRP10 gene has been associated with Parkinson's disease (PD), Parkinson's disease with dementia (PDD), and dementia with Lewy bodies (DLB). The aim of the present study was to evaluate the presence of mutations of the LRP10 gene in patients with PD or DLB from Southern Italy. Sequencing analysis revealed only 2 missense and 3 synonymous variants in patients and control subjects and a rare variant p.L622F in a PD case. These results suggest that LRP10 mutations are not a frequent cause of PD and DLB in Southern Italy.

Lewy Body Diseasemedicine.medical_specialtyNeurologyParkinson's diseaseLRP10 . Parkinson’s disease . Dementia with Lewy bodiesDermatologyDiseasebehavioral disciplines and activities03 medical and health sciences0302 clinical medicineAlzheimer DiseaseInternal medicineDementia with Lewy bodies; LRP10; Parkinson's disease.mental disordersmedicineDementiaMissense mutationHumans030212 general & internal medicineNeuroradiologyDementia with Lewy bodiesbusiness.industryParkinson DiseaseGeneral Medicinemedicine.diseasenervous system diseasesPsychiatry and Mental healthItalyMutationSettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusiness030217 neurology & neurosurgery
researchProduct